Key result
Abluminus DES+ combines a sirolimus-eluting stent and drug-coated balloon to reduce adverse outcomes in diabetes.
Why the study?
Despite advances in PCI techniques and stent platforms, clinical outcomes in patients with diabetes mellitus and coronary artery disease have improved little compared with non-diabetic patients.
Abluminus DES+ is a novel biodegradable polymer sirolimus-eluting stent deployed with a drug-coated balloon designed to address the complex coronary artery disease seen in patients with diabetes mellitus.
Diabetes mellitus (DM) is a rising global epidemic affecting more than 10% of the world population and predisposes patients to develop highly progressive and complex coronary artery disease. Despite numerous advancements in percutaneous coronary intervention procedural techniques and coronary stent platforms, clinical outcomes in DM patients have improved little compared with non-DM patients. Abluminus DES+, a biodegradable polymer sirolimus-eluting stent deployed with a drug-coated balloon, has been specifically designed to provide adequate coverage for DM patients and reduce adverse clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Goel et al. (2020) conducted a review in Coronary Artery Disease in Patients with Diabetes Mellitus. Abluminus DES+ was evaluated. Abluminus DES+, a biodegradable polymer sirolimus-eluting stent deployed with a drug-coated balloon, is designed to reduce adverse clinical outcomes in patients with diabetes mellitus.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More on Coronary artery diseaseMore from Future Cardiology